EP0364492A1 - Virusproteine mit reduzierter o-glykosylierung - Google Patents

Virusproteine mit reduzierter o-glykosylierung

Info

Publication number
EP0364492A1
EP0364492A1 EP88906390A EP88906390A EP0364492A1 EP 0364492 A1 EP0364492 A1 EP 0364492A1 EP 88906390 A EP88906390 A EP 88906390A EP 88906390 A EP88906390 A EP 88906390A EP 0364492 A1 EP0364492 A1 EP 0364492A1
Authority
EP
European Patent Office
Prior art keywords
glycoprotein
prv
insect
virus
pseudorabies virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88906390A
Other languages
English (en)
French (fr)
Inventor
Darrell R. Thomsen
Leonard E. Post
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of EP0364492A1 publication Critical patent/EP0364492A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to- viral glycoproteins having reduced 0- linked glycosylation.
  • the invention also relates to methods for producing such glycoproteins. More specifically, the invention relates to a pseudorabies virus glycoprotein having reduced 0-linked glycosylation and methods for producing . said glycoprotein with baculovirus vectors in insect cell hosts. These glycoproteins having reduced 0-linked glycosylation are useful for protecting animals against infection by the viruses they are derived from.
  • PRV Pseudorabies virus
  • PRV infection are variously called infectious Bulbar paralysis, Aujeszky's disease, and mad itch.
  • Infections are known in important domestic animals such as swine, cattle, dogs, cats, sheep, rats and mink.
  • the host range is very broad and includes most mammals and, experimentally at least, many kinds of birds (for a detailed list of hosts, see D.P. Gustafson, "Pseudo ⁇ rabies", in Diseases of Swine, 5th ed. , A.D. Leman et al., eds. , (1981)).
  • the disease is fatal.
  • Adult swine and possibly rats are not killed by the disease and are therefore carriers.
  • PRV vaccines have been produced by a variety of techniques and vaccination in endemic areas of Europe has been practiced for more than 15 years. Losses have been reduced by vaccination, but vaccina- tion has maintained the virus in the environment. No vaccine has been produced that will prevent infection. Vaccinated animals that are exposed to virulent virus survive the infection and then shed more virulent virus. Vaccinated animals may therefore harbor a latent infection that can flare up again. (See, D.P. Gustafson, supra) .
  • PRV is a herpesvirus.
  • the herpesviruses generally are among the most complex of animal viruses. Their genomes encode at least 50 virus specific proteins and contain upwards of 150,000 nucleotides. Among the most immunologically reactive proteins of herpesviruses are the glycoproteins found, among other places, in virion membranes and the membranes of infected cells.
  • the literature on PRV glycoproteins refers to at least four viral glycoproteins (T. Ben-Porat and A.S. Kaplan, Virology, 41, pp. 265-73 (1970); A.S. Kaplan and T. Ben-Porat, Proc. Natl. Acad. Sci. USA, 66, pp. 799-806 (1970)).
  • European patent publication number 0 127 839 and European patent publication number 0 155 476 refer to methods for producing recom ⁇ binant baculovirus expression vectors for expression of selected genes together with such vectors. They do not disclose the use of such vectors to produce viral glycoproteins having less 0-linked glycosylation than the naturally occurring proteins for use in vaccines. Both of these documents are incorporated herein by reference. S. Alexander and J.H. Elder, "Carbohydrate Dramatically Influ ⁇ ences Immune Reactivity of Antisera to Viral Glycoprotein Antigens", Science, 226, pp. 1328-30 (1984) demonstrated that viral glyco ⁇ proteins with N-linked carbohydrate removed by endoglycosidase F had varying antigenic effects.
  • Heteroantisera prepared against virus were virtually unreactive toward the viral glycoproteins after N- linked carbohydrate removal.
  • the reactivity of monoclonal antibodies prepared to glycosylated antigen in most cases improved, while in a smaller number of cases it stayed the same, or decreased in reactivity when reacted with the antigen without N-linked carbo- hydrate.
  • Most antibodies to synthetic peptide sequences also improved in reactivity after N- inked carbohydrate removal.
  • a protein expressed in insect cells will be rich in mannose and lacking sialic acid. At this point, the ramifica ⁇ tions of this are not clear and are likely to be of more or less concern depending on the end use of the product.
  • proteins expressed in insect cells are frequently smaller than their native counter ⁇ parts. We attribute this to less complex glycosylation and perhaps substantial hydrolysis of the high mannose complex unit [citation omitted] . This has not been directly determined for heterologous gene products of the baculovirus expression system. "With regard to the possible in vivo physiological effects of this glycosylation difference, much work needs to be done. We have no clear-cut case where the glycosylation difference has altered biological activity of a protein but do consider that this will inevitably be observed.”
  • M.W. Wathen and L.K. Wathen, J. Virol., 51, pp. 57-62 (1984) refer to a PRV containing a mutation in a viral glycoprotein (g ⁇ 50)
  • the mupant " utilizing neutralizing monoclo ⁇ nal antibody directed against gp50 Iff- and a method for selecting, the mupant " utilizing neutralizing monoclo ⁇ nal antibody directed against gp50. Wathen and Wathen also indicate that a monoclonal antibody directed against gp50 is a strong neutral- izer of PRV, with or without the aid of complement, and that polyval ⁇ ent immune serum is highly reactive against gp50, therefore conclud-
  • gp50 may be one of the important PRV immunogens.
  • monoclonal antibodies that react with the 98,000 MW envelope glycoprotein neutralize PRV infectivity but that monoclonal antibodies directed against some of the other membrane glycoproteins have very little neutralizing
  • BamHI 7 fragment of PRV codes for at least three other viral proteins of 65K, 60K, and 40K MW. They do not disclose or suggest a viral glycoprotein having reduced 0-linked glycosylation of the instant invention or the production of similar polypeptides in insect cells with baculovirus vectors.
  • European published patent application 0 133 200 refers to a diagnostic antigenic factor to be used together with certain lectin-- bound PRV glycoprotein subunit vaccines to distinguish carriers and noncarriers of PRV.
  • G. E. Smith, et al. "Modification and Secretion of Human Interleukin 2 Produced in Insect Cells by a Baculovirus Expression Vector," Proc. Natl. Acad. Sci. U.S.A., 82, pp. 8404-08 (1985) refer to production of IL-2 by inserting its cDNA into the genome of Autographa califomica nuclear polyhedrosis virus adjacent to the polyhedrin promoter and then using this recombinant virus to infect an insect cell host. They indicated that there was no evidence that the recombinant IL-2 produced was glycosylated. They do not disclose or suggest producing viral glycoproteins having a lower amount of 0- linked glycosylation than their naturally occurring homologs for use as vaccines.
  • the present invention relates to viral glycoproteins having a lower amount of 0-linked glycosylation than their naturally occurring glycoprotein, more particularly wherein said glycoprotein is a pseudorabies virus glycoprotein, and even more particularly pseudo ⁇ rabies virus gp50.
  • the glycoproteins having a lower amount of glycosylation than the natural glycoproteins are produced by an insect cell host infected with a baculovirus vector comprising a DNA sequence encoding said glycoprotein.
  • insect cell host referred to above is selected from the group consisting of Spodoptera frugiperda, Bomhyx mori , Trichoplusia ni , and other lepidopteran cell lines.
  • Intact worms can also be used as hosts for example, for AcNPV vectors, cabbage loopers or fall armyworms. See Maeda, et al. , supra.
  • the glycoprotein having a lower amount of glycosylation than the natural glycoprotein is produced by a Spodop ⁇ tera frugiperda insect cell host infected with a baculovirus vector comprising a DNA sequence encoding said glycoprotein, more specifi ⁇ cally, gp50.
  • the glycoprotein is a pseudo ⁇ rabies virus glycoprotein, more specifically, gp50.
  • the insect host cell used in the method set forth above is Spodoptera frugiperda. DETAILED DESCRIPTION OF THE INVENTION
  • the glycoprotein encoded by the gene was defined as a glycoprot ⁇ ein that reacted with a particular monoclonal antibody. This glycoprotein did not correspond to any of the previously known PRV glycoproteins.
  • Wathen and Wathen mapped a mutation resistant to the monoclonal antibody, which, based on experience with herpes simplex virus (e.g., T.C. Holland et al., J. Virol., 52, pp.566-74 (1984)), indicated that they had mapped the location of the structural gene for gp50.
  • Wathen and Wathen mapped the gp50 gene to the smaller Sall/BamHI fragment from within the BamHI 7 fragment of PRV. Rea et al, supra, have mapped the PRV glycoprotein gX gene to the same region.
  • gp50 gene under control of the polyhedrin promoter in the baculovirus Autographa califomica nuclear polyhedrosis virus (AcNPV) .
  • AcNPV Autographa califomica nuclear polyhedrosis virus
  • Two forms of the gene were inserted into AcNPV: (1) the intact gene encoding the complete gp50 amino acid sequence to produce a recombinant virus designated AcNPV-gp50, and (2) the gene with the base pairs encoding the anchor sequence of gp50 deleted to produce a recombinant virus designated AcNPV-gp50T.
  • AcNPV-gp50-infected cells produced a cellular form of gp50 and AcNPV-gp50T-infected cells produced a truncated form of g ⁇ 50 which is secreted into the medium. Both of these forms of gp50 produced in insect cells had a sig ⁇ nificantly lower molecular weight than the same proteins produced in mammalian cells because of reduced 0-linked glycosylation.
  • the gp50 produced in insect cells is, however, labeled with • ' ⁇ ⁇ 'C-glucosamine. Since the gp50 sequence contains no N-linked glycosylation sites (E.A.
  • Insect cells infected with AcNPV- p50 were used to immunize mice. After a series of three immunizations with 10° infected cells, most of the mice survived a challenge with virulent PRV. -
  • the gene encoding gp50 mapped to the BamHI 7 fragment of the PRV DNA.
  • the BamHI 7 fragment from PRV can be derived from plasmid pPRXhl (also known as pUC1129) and fragments convenient for DNA sequence analysis can be derived by standard subcloning procedures.
  • Plasmid pUC1129 is available from E. coli HB101, NRRL B-15772. This culture is available from the permanent collection of the Northern Regional Research Center Fermentation Laboratory (NRRL), U.S. Department of Agriculture, in Peoria, Illi ⁇ nois, U.S.A.
  • E. coli HB101 containing pUC1129 can be grown up in L-broth by well known procedures.
  • the culture is grown to an optical density of 0.6 after which chloramphenicol is added and the culture is left to shake overnight.
  • the culture is then lysed by, e.g., using high salt SDS and the supernatant is subjected to a cesium chloride/ethidium bromide equilibrium density gradient centrifugation to yield the plasmids.
  • the a ino acid sequence of PRV glycoprotein gp50 is set forth in Chart A of PCT/US86/01761.
  • - Glycoproteins having a smaller amount of 0-linked glycosylation than the naturally occurring glycoproteins produced by the method of the instant invention and displaying PRV glycoprotein antigenicity include the sequence set forth in Chart A and any portion of the polypeptide sequence which is capable of eliciting an immune response in an animal, e.g., a mammal, which has been injected with the polypeptide sequence, and also immunogenically functional analogs of the polypeptides.
  • the entire gene coding for the PRV glycoprotein can be employed in constructing the vectors and infecting the insect host cells to express the PRV glycoprotein having reduced 0-lihked glycosylation, or fragments of the gene coding for the PRV glycoprotein can be em ⁇ ployed, whereby the resulting insect host cell will express polypep ⁇ tides displaying PRV antigenicity.
  • Any fragment of the PRV glycopro ⁇ tein gene can be employed which results in the expression of a polypeptide which is an immunogenic fragment of the PRV glycoprotein or an analog thereof.
  • the degeneracy of the genetic code permits easy substitution of base pairs to produce functionally equivalent genes and fragments thereof encoding polypep ⁇ tides displaying PRV glycoprotein antigenicity. These functional equivalents also are included within the scope of the invention.
  • PRV glycoproteins having non-essential amino acid substitutions which are also well-known in the art, and deletions, which do not affect the PRV antigenicity of the polypeptides.
  • Charts A and B are set forth to illustrate the constructions of the Examples. Certain conventions are used to illustrate plasmids and DNA fragments as follows:
  • the single line figures represent both circular and linear double-stranded DNA.
  • pD50 was cut with EcoRI and the ends made blunt by treatment with T4 DNA polymerase. BamHI linkers were then ligated on and the fragment so produced was treated with BamHI.
  • the fragment, containing the gp50 gene (about 1300 base pairs), was isolated by agarose gel electrophoresis.
  • Plasmid pAc373 (7.1 kb) is a baculovirus expression vector having a unique BamHI site immediately downstream from the polyhedron promoter of AcNPV.
  • the plasmid is available from Professor Max Summers of the Department of Entomology, Texas A&M University, College Station, Texas 77843 and is fully described in Mol. and Cell. Biol., 3, pp. 2156-65 (1983) and in European patent publication number 0 127 839. It can also be obtained from the Agricultural Research Culture Collection (NRRL) where it has been assigned accession number NRRL B-15778.
  • pAc373 was digested with BamHI, and the ends were dephosphory- lated with bacterial alkaline phosphatase.
  • the BamHI fragment containing the gp50 gene from above was ligated into the linearized pAc373 to produce plasmid pAcgp50-4.
  • Recombinants having the gp50 gene in the proper orientation with relation to the polyhedron promoter were determined by digestion with Sail which produced a 975 base pair fragment for clones with the correct orientation.
  • Example 2 Construction of Plasmid pAcgp50T-5 We constructed this plasmid to put the gene encoding the truncated secreted form of gp50 (see PCT/US86/01761) into the pAc373 vector.
  • plasmid pD50T was constructed exactly -li ⁇ the same as plasmid pDIE50T was constructed in PCT/US86/01761, chart L and materials related thereto, except that pD50 was the starting plasmid instead of ⁇ DIE50.
  • pD50 is digested with Sail and EcoRI a 4.2 kb Sall/Eco RI fragment is produced instead of the 5.0 kb fragment for pDIE50.
  • the only difference between the resulting plasmids is that the cytomegalovirus (CMV) promoter is not in plasmid pD50T and a BamHI site remains.
  • CMV cytomegalovirus
  • pD50T was manipulated to introduce the gene for the truncated gp5° into the pAc373 vector to produce pAcgp50-T-5.
  • the same 975 bp Sail fragment was diagnostic for the correct orientation of the sequence encoding the truncated gp50.
  • the plasmids produced above in Examples 1 and 2 were co-trans- fected along with baculovirus AcNPV DNA into Spodoptera frugiperda
  • Recombinant viruses containing the gp50 genes were enriched by limited dilution of approximately 10 ⁇ plaque forming units per well in microtiter wells, followed by hybridization with - ⁇ p-iabeled g ⁇ 50 DNA to detect wells where recombinant viruses were growing. Recombinant viruses were isolated by plating out dilute virus and picking individual plaques that lacked occluded virus. The viruses were plaque-purified four times to be sure that occlusion positive virus was eliminated before growing up virus stocks.
  • Recombinant viruses were isolated from transfections with both pAcgp50-4 and pAcgp50T-5 and were designated AcNPV-gp50 and AcNPV- gp50T respectively.
  • Sf9 cells are infected with one of the recombinant viruses produced in Example 3 at a multiplicity of infection of at least 1.0 plaque forming unit per cell.
  • the cells are suspended in Grace's medium, gently centrifuged out, and resuspended in Grace's medium lacking me hionine but to which 100 microcuries per ml of --S-methionine is added.
  • Samples are harvested and gp50 expression is analyzed by immunoprecipita ion as described in E.A. Petrovskis, et al, J. Virol., 59, pp. 216-23 (1986).
  • AcNPVgpSO-infected cells produced three forms of gp50, having molecular weights of 44, 46 and 47 kd.
  • AcNPVgp50T-infected cells produced a form of gp50 having a molecular weight of about 41 kd.
  • Two forms of gp50 having molecular weights of 43 and 44 kd were found in the medium of these latter infected cells.
  • the lower molecular weight polypeptides correspond to the expected molecular weight of the protein backbone of gp50 molecules with little or no 0-linked glycosylatio .
  • Table 1 sets forth the protection of mice from challenge by virulent PRV by immunization with gp50 produced in Sf9 cells or tissue plasminogen activator (tPA) produced in Sf9 cells as a control (AcNPVgp50 or AcNPV-tPA respectively) . Mice were immunized at 28 days, 18 days and 7 days prior to challenge.
  • gp50 produced in Sf9 cells
  • tPA tissue plasminogen activator
  • a vaccine prepared utilizing a gp50 protein of the instant invention or an immunogenic fragment thereof can consist of fixed host cells, a host cell extract, or a partially or completely purified PRV glycoprotein preparation from the host cells.
  • the gp50 immunogen prepared in accordance with the present invention is preferably free of PRV virus.
  • the vaccine immunogen of the invention is composed substantially entirely of the desired im ⁇ munogenic PRV gp50 polypeptide and/or other PRV polypeptides display ⁇ ing PRV antigenicity.
  • the immunogen can be prepared in vaccine dose form by well-known procedures.
  • the vaccine can be administered intramuscularly, subcu- taneously or intranasally.
  • the immunogen may be combined with a suitable carrier, for example, it may be administered in water, saline or buffered vehicles with or without various adjuvants or immunomodulating agents including aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum), beryllium sulfate, silica, kaolin, carbon, water-in-oil emulsions, oil-in-water emul ⁇ sions, muramyl dipeptide, bacterial endotoxin, lipid X, Corynebac- terium parvu (Propionobacterium acnes), Bordetella pertussis, polyribonucleotides, sodium alginate, lanolin, lysolecithin, vitamin A, saponin, liposomes, levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants.
  • adjuvants or immunomodulating agents including aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (
  • adjuvants are available commer ⁇ cially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.). Another suitable adjuvant is Freund's Incomplete Adjuvant (Difco Laboratories, Detroit, Mich ⁇ igan) .
  • the proportion of immunogen and adjuvant can be varied over a broad range so long as both are present in effective amounts.
  • aluminum hydroxide can be present in an amount of about 0.5% of the vaccine mixture (AI2O3 basis).
  • the concentration of the immunogen can range from about 1.0 ⁇ g to about 100 mg per animal. In pigs, a preferable range is from about 100 ⁇ g to about 3.0 mg per pig.
  • a suitable dose size is about 1-10 ml, preferably about 1.0 ml. Accordingly, a dose for intramuscular injection, for example, would comprise 1 ml containing 1.0 mg of immunogen in admixture with 0.5% aluminum hydroxide. Comparable dose 5 forms can also be prepared for parenteral administration to baby pigs, but the amount of immunogen per dose will be smaller, for example, about 0.25 to about 1.0 mg per dose.
  • the first dose can be given from about several months to about 5 to 7
  • the second dose of the vaccine then should be administered some weeks after the first dose, for example, about 2 to 4 weeks later, and vaccine can then be administered up to, but prior to, farrowing.
  • the vaccine can be administered as a single 2 ml dose, for example, at about 5 to 7 weeks prior to
  • the vaccine may also be combined with other vaccines for other diseases to produce multivalent vaccines. It may also be combined with other medicaments, for example, antibiotics.
  • a pharmaceutically acceptable salt for example
  • 25 effective amount of the vaccine can be employed with a pharmaceuti ⁇ cally acceptable carrier or diluent to vaccinate animals such as swine, cattle, sheep, goats, and other mammals.
  • Plasmid pAc373 is digested with BamHI and BAP to produce fragment 3.
  • poly P (d) Fragments 2 and 3 are ligated to produce plasmid pAcgp50-4.
  • Plasmid pAcgp50T-5 is produced from plasmid pD50T by the same manipulations as were done in Chart B, but starting with pD50T.
EP88906390A 1987-06-30 1988-06-17 Virusproteine mit reduzierter o-glykosylierung Withdrawn EP0364492A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6821187A 1987-06-30 1987-06-30
US68211 1987-06-30

Publications (1)

Publication Number Publication Date
EP0364492A1 true EP0364492A1 (de) 1990-04-25

Family

ID=22081120

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88906390A Withdrawn EP0364492A1 (de) 1987-06-30 1988-06-17 Virusproteine mit reduzierter o-glykosylierung

Country Status (5)

Country Link
EP (1) EP0364492A1 (de)
JP (1) JPH02504103A (de)
KR (1) KR890701745A (de)
AU (1) AU2083788A (de)
WO (1) WO1989000196A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU616211B2 (en) * 1987-03-09 1991-10-24 Upjohn Company, The Transgenic animal cells resistant to viral infection
FR2631974B1 (fr) * 1988-05-31 1992-12-11 Agronomique Inst Nat Rech Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
ATE119939T1 (de) * 1989-06-27 1995-04-15 Smithkline Beecham Biolog Verbindungen.
US5317097A (en) * 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
US5298239A (en) * 1991-10-07 1994-03-29 The Research Foundation Of State University Of New York Mutations rendering platelet glycoprotein IB α less reactive

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127839B1 (de) * 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Verfahren zur Herstellung eines rekombinanten Baculovirus-Expressionsvektors
US4877737A (en) * 1985-09-06 1989-10-31 Prutech Research And Development Partnership Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same
WO1987003206A1 (en) * 1985-11-25 1987-06-04 Quash Gerard A Modified viral glycoproteins, diagnostic and therapeutic uses therefore

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8900196A1 *

Also Published As

Publication number Publication date
WO1989000196A1 (en) 1989-01-12
JPH02504103A (ja) 1990-11-29
AU2083788A (en) 1989-01-30
KR890701745A (ko) 1989-12-21

Similar Documents

Publication Publication Date Title
EP0231209B1 (de) Virus-impfstoff
EP0732340B1 (de) Expression in der selben Zelle von Polypeptide vom schweinen reproduktiven und respiratorischen Syndrom
CA2088599A1 (en) Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system
JP4750024B2 (ja) Ｓａｒｓの免疫原を発現するベクター、そのようなベクター又はその発現産物を含有する組成物、並びにその作製及び使用の方法及びアッセイ
JP2568384B2 (ja) 偽狂犬病ウイルスワクチン用ポリペプチド、その製法、およびそれを含有するワクチン
EP0364492A1 (de) Virusproteine mit reduzierter o-glykosylierung
US5674709A (en) Pseudorabies virus protein
US6172186B1 (en) Pseudorabies virus protein
WO1989010965A2 (en) Glycoprotein h of herpes viruses
US6261563B1 (en) Pseudorabies virus protein
US5275934A (en) Method of detecting viral infection in vaccinated animals
DK175114B1 (da) Rekombinant DNA-molekyle, værtscelle transformeret dermed og fremgangsmåde til fremstilling af et polypeptid ved anvendelse af det rekombinante DNA-molekyle
JP2810364B2 (ja) 偽狂犬病ウイルス蛋白質
CA1325610C (en) Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
EP0263207A1 (de) Virus-Vakzin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19891214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920519

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920930